Cerbios-Pharma gains new director of commercial business development

Will help firm to grow and strengthen HPAPI services

Stefano Console has joined Cerbios-Pharma as director of commercial business development.

Prior to joining Cerbios, Console was business and financial director at Micro-Macinazione.

Cerbios-Pharma is a Swiss firm based in Lugano specialising in the development and manufacturing of chemical and biological APIs.

APIs made by Cerbios cover small molecules (Chemical Division), large molecules and probiotics (Biological Division).

The Chemical Division specialises not only in reduced folates, but also in the manufacturing of High Potency Active Ingredients (HPAIs) with long-term experience in Vitamin D derivatives requiring sophisticated production units with high containment levels.

The Biological Division specializes in the research, development and production of Probiotics as active pharmaceutical ingredients, pharmaceutical finished products and feed additives.

You may also like

Manufacturing

Cerbios-Pharma opens HPAI plant

Investment in Barbengo, Switzerland, is part of an expansion strategy started in 1996
Ingredients

Safe and accurate flow measurement for pharmaceutical production

Oval Gear (OG) meters from Titan Enterprises, fitted with a Namur sensor, provide consistent, accurate measurement across a wide range of liquids, from low-viscosity solvents to more viscous pharmaceutical ingredients
Manufacturing

NorthStar and QSA Global sign multi-year partnership to secure actinium-225 supply chain

NorthStar Medical Radioisotopes and QSA Global have announced a new strategic services agreement to support commercial-scale production of actinium-225 through a closed-loop radium-226 target supply and recycling programme for targeted alpha therapies
Ingredients

Pioneering AAV approach unlocks cause of rheumatoid arthritis pain

Karolinska Institute researchers use AAV products to uncover neural mechanisms behind rheumatoid arthritis pain
You need to be a subscriber to read this article.
Click here to find out more.
Manufacturing

Pharma supply chains face record drug shortages as geopolitical, cyber and quality risks converge

A new Moody's report identifies four compounding risk factors driving pharmaceutical supply chain instability and warns that siloed risk management is leaving the sector dangerously exposed
You need to be a subscriber to read this article.
Click here to find out more.
Manufacturing

Rice-ing to the occasion: how plant-based excipients are gaining ground in pharmaceutical manufacturing

As clean-label expectations migrate from health foods into pharmaceutical supply chains, natural ingredient supplier RIBUS says that rice-based excipients are becoming a credible alternative to synthetic standards
Ingredients

The impact of Brexit on raw materials testing for the pharmaceutical industry (2026 update)

Since the UK departed from the EU, the pharmaceutical regulatory landscape has undergone significant and lasting change; whereas early uncertainty has largely subsided, the system has evolved into a stable but more complex dual framework
Subscribe now